Insider Buying: ProtoKinetix, Inc. (PKTX) CEO Purchases 448,500 Shares of Stock

Share on StockTwits

ProtoKinetix, Inc. (OTCMKTS:PKTX) CEO Clarence Edward Smith purchased 448,500 shares of the company’s stock in a transaction on Friday, June 15th. The stock was acquired at an average price of $0.10 per share, for a total transaction of $44,850.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Clarence Edward Smith also recently made the following trade(s):

  • On Monday, June 11th, Clarence Edward Smith acquired 203,700 shares of ProtoKinetix stock. The shares were bought at an average price of $0.08 per share, for a total transaction of $16,296.00.
  • On Tuesday, June 5th, Clarence Edward Smith acquired 288,729 shares of ProtoKinetix stock. The shares were bought at an average price of $0.07 per share, for a total transaction of $20,211.03.
  • On Friday, May 25th, Clarence Edward Smith acquired 228,100 shares of ProtoKinetix stock. The shares were bought at an average price of $0.06 per share, for a total transaction of $13,686.00.
  • On Tuesday, May 22nd, Clarence Edward Smith acquired 434,047 shares of ProtoKinetix stock. The shares were bought at an average price of $0.05 per share, for a total transaction of $21,702.35.

ProtoKinetix traded down $0.02, hitting $0.08, on Friday, according to Marketbeat.com. 246,450 shares of the company were exchanged, compared to its average volume of 91,933. ProtoKinetix, Inc. has a twelve month low of $0.03 and a twelve month high of $0.12.

About ProtoKinetix

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in food and crop preservation at freezing temperatures.

Receive News & Ratings for ProtoKinetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProtoKinetix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply